Biogen (BIIB) PT Lowered to $343 at Wells Fargo
Tweet
Share
E-mailGet Alerts BIIB Hot Sheet
Price: $204.51 -2.11%
Rating Summary:
27 Buy, 16 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 10 | New: 12
Rating Summary:
27 Buy, 16 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 14 | Down: 10 | New: 12
Join SI Premium – FREE
Wells Fargo analyst Mohit Bansal lowered the price target on Biogen (NASDAQ: BIIB) to $343.00 (from $350.00) while maintaining a Overweight rating.
You May Also Be Interested In
- Freedom Broker Downgrades Karooooo Ltd. (KARO) to Hold
- Synapticure Launches Groundbreaking Ataxia Care Program, Expanding Access to Specialized Neurology Nationwide
- Manpower Inc. (MAN) PT Raised to $55 at UBS Following Better-Than-Expected Q2 Results
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
